An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma

Trial Profile

An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Interferon alpha
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 12 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
    • 12 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
    • 09 Nov 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top